Advaxis Inc. (ADXS)

2.32
0.03 1.31
NASDAQ : Health Technology
Prev Close 2.29
Open 2.34
Day Low/High 2.25 / 2.37
52 Wk Low/High 2.08 / 26.82
Volume 42.22K
Avg Volume 914.60K
Exchange NASDAQ
Shares Outstanding 8.01M
Market Cap 18.25M
EPS -19.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

FDA Lifts Partial Clinical Hold On Phase 3 AIM2CERV Study Of Axalimogene Filolisbac

FDA Lifts Partial Clinical Hold On Phase 3 AIM2CERV Study Of Axalimogene Filolisbac

Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.

Advaxis Announces Two Poster Presentations At The Frontiers In Cancer Immunotherapy Conference

Advaxis Announces Two Poster Presentations At The Frontiers In Cancer Immunotherapy Conference

Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being...

Advaxis Announces Appointment Of Dr. Robert Petit To Chair Of Scientific Advisory Board And Departure As Chief Scientific Officer

Advaxis Announces Appointment Of Dr. Robert Petit To Chair Of Scientific Advisory Board And Departure As Chief Scientific Officer

Advaxis, Inc.  (NASDAQ:ADXS) (the "Company"), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.

Advaxis To Participate In Five Upcoming Industry Conferences

Advaxis To Participate In Five Upcoming Industry Conferences

Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in five upcoming industry conferences: BioNJ 9 th Annual BioPartnering...

Advaxis Announces Pricing Of Its Public Offering Of Common Stock

Advaxis Announces Pricing Of Its Public Offering Of Common Stock

Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of...

Advaxis, Inc. Announces Proposed Public Offering Of Common Stock

Advaxis, Inc. Announces Proposed Public Offering Of Common Stock

Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering...

ADXS-PSA In Combination With KEYTRUDA® Prolonged Survival In Metastatic Castration-Resistant Prostate Cancer

ADXS-PSA In Combination With KEYTRUDA® Prolonged Survival In Metastatic Castration-Resistant Prostate Cancer

Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated data from the Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant...

Preliminary Data From Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity And Clinical Activity

Preliminary Data From Phase 1 Study Evaluating ADXS-NEO Suggest Rapid Immunogenicity And Clinical Activity

Advaxis, Inc.  (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-NEO data in a poster discussion entitled " Safety and...

Advaxis Announces Reverse Stock Split

Advaxis Announces Reverse Stock Split

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that its Board of Directors has approved a one-for-fifteen (1-for-15) reverse stock...

Advaxis Granted U.S. Patent Relating To Axalimogene Filolisbac

Advaxis Granted U.S. Patent Relating To Axalimogene Filolisbac

Advaxis, Inc.  (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the U.

Advaxis Reports First Quarter Fiscal 2019 Financial Results And Provides Clinical Pipeline Update

Advaxis Reports First Quarter Fiscal 2019 Financial Results And Provides Clinical Pipeline Update

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the first quarter ended...

Advaxis Announces Presentations Of ADXS-NEO And ADXS-PSA Data At Upcoming American Association For Cancer Research Annual Meeting

Advaxis Announces Presentations Of ADXS-NEO And ADXS-PSA Data At Upcoming American Association For Cancer Research Annual Meeting

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today two poster presentations at the upcoming American Association for Cancer Research (AACR)...

Advaxis Announces Enrollment Of The First Patient In Its Phase 1/2 Trial For ADXS-HOT In The Treatment Of Non-Small Cell Lung Cancer

Advaxis Announces Enrollment Of The First Patient In Its Phase 1/2 Trial For ADXS-HOT In The Treatment Of Non-Small Cell Lung Cancer

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has initiated its Phase 1/2 clinical trial to evaluate ADXS-503, part of the Company's...

Advaxis Presents An Overview Of Its Lm Platform And Neoantigen-Directed Programs At The Immuno-Oncology 360° Conference

Advaxis Presents An Overview Of Its Lm Platform And Neoantigen-Directed Programs At The Immuno-Oncology 360° Conference

Advaxis, Inc. (NASDAQ:ADXS), (the Company) a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of the progression of its Lm platform from discovery to...

Advaxis To Present An Overview Of Its Lm Platform And New Information On Its Neoantigen-Directed Therapy Programs At The Immuno-Oncology 360° Conference

Advaxis To Present An Overview Of Its Lm Platform And New Information On Its Neoantigen-Directed Therapy Programs At The Immuno-Oncology 360° Conference

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that an overview of the Company's proprietary Lm platform and new information regarding...

Data Highlighting Potential Benefits Of Lm Platform Presented At 2019 Keystone Symposia Conference On Cancer Vaccines

Data Highlighting Potential Benefits Of Lm Platform Presented At 2019 Keystone Symposia Conference On Cancer Vaccines

Advaxis, Inc.  (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that two presentations highlighting the potential of Advaxis vectors to generate T cell...

Advaxis' Phase 3 AIM2CERV Study Placed On Partial Clinical Hold By FDA Related To CMC Requests

Advaxis' Phase 3 AIM2CERV Study Placed On Partial Clinical Hold By FDA Related To CMC Requests

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.

Advaxis Reports Fiscal Year 2018 Financial Results And Provides A Business Update

Advaxis Reports Fiscal Year 2018 Financial Results And Provides A Business Update

Advaxis, Inc. (NASDAQ: ADXS) (the Company), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces its financial results for the fiscal year ended October 31, 2018 and...

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis To Host Business Update Conference Call On January 15, 2019

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Tuesday, January 15, 2019.

Advaxis To Present At LD Micro Main Event

Advaxis To Present At LD Micro Main Event

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis To Present Poster Entitled "Natural Killer (NK) Cells Orchestrate The Antitumor Activities Of Listeria Monocytogenes (Lm)-Based Immunotherapy" At Society For Immunotherapy Of Cancer Annual Meeting

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC).

Advaxis Provides Update On Clinical Pipeline

Advaxis Provides Update On Clinical Pipeline

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded,...

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis To Host Business Update Conference Call On November 2, 2018

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis To Present At The Cantor Fitzgerald Global Healthcare Conference

Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Closing Of Its Public Offering Of Common Stock And Warrants

  Advaxis, Inc. (NASDAQ: ADXS) ("Advaxis" or the "Company") announced today the closing of its previously announced underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis Reports Fiscal 2018 Third Quarter Business Highlights And Financial Results

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended...

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis Announces Pricing Of Its Public Offering Of Common Stock And Warrants

Advaxis, Inc. (NASDAQ:ADXS) ("Advaxis" or the "Company") announced today the pricing of an underwritten public offering of 16,666,666 shares of its common stock and warrants to purchase up to 14,166,666 shares of common stock.

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. Announces Proposed Underwritten Public Offering Of Common Stock And Warrants

Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company") announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a...

TheStreet Quant Rating: E+ (Sell)